[
  {
    "ts": null,
    "headline": "We Think Gilead Sciences' (NASDAQ:GILD) Profit Is Only A Baseline For What They Can Achieve",
    "summary": "NasdaqGS:GILD 1 Year Share Price vs Fair Value Explore Gilead Sciences's Fair Values from the Community and select...",
    "url": "https://finnhub.io/api/news?id=2757417365d87b54f9a657cfbd1743266a18ef811822c1ffba20696ce6f7fe22",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755168995,
      "headline": "We Think Gilead Sciences' (NASDAQ:GILD) Profit Is Only A Baseline For What They Can Achieve",
      "id": 136344888,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "NasdaqGS:GILD 1 Year Share Price vs Fair Value Explore Gilead Sciences's Fair Values from the Community and select...",
      "url": "https://finnhub.io/api/news?id=2757417365d87b54f9a657cfbd1743266a18ef811822c1ffba20696ce6f7fe22"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences’s Q2 Earnings Call: Our Top 5 Analyst Questions",
    "summary": "Gilead Sciences delivered a better-than-expected second quarter, propelled by the strong performance of its HIV portfolio and the launch of Yeztugo, its twice-yearly injectable for HIV prevention. Management attributed the 7% year-over-year HIV growth to robust demand for Biktarvy and Descovy, along with effective commercial execution. CEO Daniel O’Day highlighted, “Biktarvy continues to lead in share in major markets around the world,” and described Descovy’s quarter as its “strongest ever,” su",
    "url": "https://finnhub.io/api/news?id=3f09efb4115a18e4dc55421a3da49f290d304d0068ecfb8c1dc82a4aa0f9c5e4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755149613,
      "headline": "Gilead Sciences’s Q2 Earnings Call: Our Top 5 Analyst Questions",
      "id": 136344889,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences delivered a better-than-expected second quarter, propelled by the strong performance of its HIV portfolio and the launch of Yeztugo, its twice-yearly injectable for HIV prevention. Management attributed the 7% year-over-year HIV growth to robust demand for Biktarvy and Descovy, along with effective commercial execution. CEO Daniel O’Day highlighted, “Biktarvy continues to lead in share in major markets around the world,” and described Descovy’s quarter as its “strongest ever,” su",
      "url": "https://finnhub.io/api/news?id=3f09efb4115a18e4dc55421a3da49f290d304d0068ecfb8c1dc82a4aa0f9c5e4"
    }
  },
  {
    "ts": null,
    "headline": "Q2 Rundown: Gilead Sciences (NASDAQ:GILD) Vs Other Therapeutics Stocks",
    "summary": "Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Gilead Sciences (NASDAQ:GILD) and its peers.",
    "url": "https://finnhub.io/api/news?id=1259fdb4fd3b68c7b93f9fec8d6999abeec8d110ac4f7a68d4a384734b3bfa0b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755142398,
      "headline": "Q2 Rundown: Gilead Sciences (NASDAQ:GILD) Vs Other Therapeutics Stocks",
      "id": 136344890,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Gilead Sciences (NASDAQ:GILD) and its peers.",
      "url": "https://finnhub.io/api/news?id=1259fdb4fd3b68c7b93f9fec8d6999abeec8d110ac4f7a68d4a384734b3bfa0b"
    }
  }
]